Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.74
IPCI's Cash to Debt is ranked lower than
73% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. IPCI: 1.74 )
Ranked among companies with meaningful Cash to Debt only.
IPCI' s Cash to Debt Range Over the Past 10 Years
Min: 0.35  Med: 10000.00 Max: No Debt
Current: 1.74
Equity to Asset 0.38
IPCI's Equity to Asset is ranked lower than
79% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. IPCI: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
IPCI' s Equity to Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.95 Max: 1
Current: 0.38
-1.36
1
F-Score: 3
Z-Score: -3.96
M-Score: -4.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -108.59
IPCI's Operating margin (%) is ranked lower than
55% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. IPCI: -108.59 )
Ranked among companies with meaningful Operating margin (%) only.
IPCI' s Operating margin (%) Range Over the Past 10 Years
Min: -9455.14  Med: -446.56 Max: -40.29
Current: -108.59
-9455.14
-40.29
Net-margin (%) -118.06
IPCI's Net-margin (%) is ranked lower than
56% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. IPCI: -118.06 )
Ranked among companies with meaningful Net-margin (%) only.
IPCI' s Net-margin (%) Range Over the Past 10 Years
Min: -5735.51  Med: -752.78 Max: -43.97
Current: -118.06
-5735.51
-43.97
ROE (%) -145.73
IPCI's ROE (%) is ranked lower than
88% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. IPCI: -145.73 )
Ranked among companies with meaningful ROE (%) only.
IPCI' s ROE (%) Range Over the Past 10 Years
Min: -233.45  Med: -201.12 Max: -103.25
Current: -145.73
-233.45
-103.25
ROA (%) -77.70
IPCI's ROA (%) is ranked lower than
81% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. IPCI: -77.70 )
Ranked among companies with meaningful ROA (%) only.
IPCI' s ROA (%) Range Over the Past 10 Years
Min: -341.48  Med: -96.04 Max: -64.63
Current: -77.7
-341.48
-64.63
ROC (Joel Greenblatt) (%) -318.81
IPCI's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. IPCI: -318.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IPCI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -9016.73  Med: -833.05 Max: -235.63
Current: -318.81
-9016.73
-235.63
Revenue Growth (3Y)(%) 142.90
IPCI's Revenue Growth (3Y)(%) is ranked higher than
98% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. IPCI: 142.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IPCI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -50.00 Max: 142.9
Current: 142.9
0
142.9
EBITDA Growth (3Y)(%) -33.90
IPCI's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. IPCI: -33.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IPCI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -10.90 Max: 44.9
Current: -33.9
0
44.9
EPS Growth (3Y)(%) -17.20
IPCI's EPS Growth (3Y)(%) is ranked lower than
66% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. IPCI: -17.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IPCI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.65 Max: 63.9
Current: -17.2
0
63.9
» IPCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IPCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 3.01
IPCI's Forward P/E is ranked higher than
93% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 19.53 vs. IPCI: 3.01 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 23.75
IPCI's P/B is ranked lower than
95% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. IPCI: 23.75 )
Ranked among companies with meaningful P/B only.
IPCI' s P/B Range Over the Past 10 Years
Min: 6.88  Med: 14.38 Max: 496
Current: 23.75
6.88
496
P/S 12.36
IPCI's P/S is ranked lower than
56% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. IPCI: 12.36 )
Ranked among companies with meaningful P/S only.
IPCI' s P/S Range Over the Past 10 Years
Min: 6.07  Med: 24.25 Max: 317
Current: 12.36
6.07
317
Current Ratio 1.04
IPCI's Current Ratio is ranked lower than
88% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. IPCI: 1.04 )
Ranked among companies with meaningful Current Ratio only.
IPCI' s Current Ratio Range Over the Past 10 Years
Min: 0.37  Med: 5.32 Max: 94.99
Current: 1.04
0.37
94.99
Quick Ratio 1.04
IPCI's Quick Ratio is ranked lower than
85% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. IPCI: 1.04 )
Ranked among companies with meaningful Quick Ratio only.
IPCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 5.32 Max: 94.99
Current: 1.04
0.37
94.99
Days Sales Outstanding 42.33
IPCI's Days Sales Outstanding is ranked higher than
70% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. IPCI: 42.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.5  Med: 10.23 Max: 352.81
Current: 42.33
0.5
352.81
Days Payable 64.65
IPCI's Days Payable is ranked higher than
54% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. IPCI: 64.65 )
Ranked among companies with meaningful Days Payable only.
IPCI' s Days Payable Range Over the Past 10 Years
Min: 30.4  Med: 39.45 Max: 58.24
Current: 64.65
30.4
58.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 44.20
IPCI's Price/Net Cash is ranked lower than
99.99% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.23 vs. IPCI: 44.20 )
Ranked among companies with meaningful Price/Net Cash only.
IPCI' s Price/Net Cash Range Over the Past 10 Years
Min: 0.02  Med: 0.63 Max: 89
Current: 44.2
0.02
89
Price/Net Current Asset Value 18.42
IPCI's Price/Net Current Asset Value is ranked lower than
99% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 4.85 vs. IPCI: 18.42 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IPCI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.02  Med: 0.64 Max: 300
Current: 18.42
0.02
300
Price/Tangible Book 12.28
IPCI's Price/Tangible Book is ranked lower than
93% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. IPCI: 12.28 )
Ranked among companies with meaningful Price/Tangible Book only.
IPCI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.02  Med: 0.58 Max: 258
Current: 12.28
0.02
258
Price/Median PS Value 0.22
IPCI's Price/Median PS Value is ranked higher than
77% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. IPCI: 0.22 )
Ranked among companies with meaningful Price/Median PS Value only.
IPCI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 3.84 Max: 183.33
Current: 0.22
0.27
183.33
Earnings Yield (Greenblatt) (%) -8.85
IPCI's Earnings Yield (Greenblatt) (%) is ranked lower than
54% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. IPCI: -8.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPCI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -671.7  Med: 0.00 Max: 0
Current: -8.85
-671.7
0

More Statistics

Revenue(Mil) $5
EPS $ -0.23
Beta2.07
Short Percentage of Float4.60%
52-Week Range $1.73 - 3.92
Shares Outstanding(Mil)24.07

Analyst Estimate

Nov15 Nov16 Nov17 Nov18
Revenue(Mil) 6 24 63 95
EPS($) -0.34 0.14 1.05 1.81
EPS without NRI($) -0.34 0.14 1.05 1.81

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I.Canada, I4A.Germany,
IntelliPharmaCeutics International Inc was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, they have developed several drug delivery systems and a pipeline of products and product candidates in various stages of development, including ANDAs filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix technologies are applied to the development of both existing and new pharmaceuticals across a range of therapeutic classes. Its scientists have developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a wide range of pharmaceuticals. These systems include several core technologies, which enable them to flexibly respond to a wide range of drug attributes and patient requirements, producing a desired controlled-release effect. The platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle and nPODDDS. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The sales of its products by its licensees outside the United States and Canada will be subject to regulatory requirements governing the testing, registration and marketing of pharmaceuticals, which vary widely from country to country.
» More Articles for IPCI

Headlines

Articles On GuruFocus.com
Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 

More From Other Websites
Intellipharmaceutics to Present at the Noble Financial Capital Markets' 12th Annual Investor... Jan 19 2016
Intellipharmaceutics to Present at the Noble Financial Capital Markets’ 12th Annual Investor... Jan 19 2016
Intellipharmaceutics Up on Positive Rexista Oxycodone Data Jan 15 2016
These 4 Stocks are Enjoying a Green Day Jan 14 2016
IntelliPharmaCeutics Surges After Company Reports Successful Bioequivalence Results Jan 14 2016
Intellipharmaceutics Announces Successful Bioequivalence Results for Abuse Deterrent Rexista™... Jan 14 2016
Intellipharmaceutics Announces Successful Bioequivalence Results for Abuse Deterrent Rexista™... Jan 14 2016
IntelliPharmaCeutics (IPCI) Rises: Stock Up 6.5% in Session Jan 12 2016
Intellipharmaceutics to Present at the Biotech Showcase™ Dec 21 2015
Intellipharmaceutics to Present at the Biotech Showcase™ Dec 21 2015
INTELLIPHARMACEUTICS INTERNATIONAL INC. Financials Dec 08 2015
The C-Suite Speaks: Micro-Cap CEOs Share Their View of the World Dec 07 2015
IntelliPharmaCeutics (IPCI) in Focus: Stock Climbs 8.3% Dec 01 2015
Intellipharmaceutics to Present at the LD Micro Main Event Nov 24 2015
Intellipharmaceutics to Present at the LD Micro Main Event Nov 24 2015
Intellipharmaceutics to Present at The MicroCap Conference Nov 23 2015
Focalin Sales May Be Weak...But It Won't Hurt This Stock Oct 10 2015
Intellipharmaceutics reports 3Q loss Oct 09 2015
Intellipharmaceutics reports 3Q loss Oct 09 2015
Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference Oct 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK